Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis
HAYES, Inc
Record ID 32018000075
English
Authors' recommendations:
Multiple sclerosis (MS) is an autoimmune disorder that impacts the spinal cord and brain. MS presents in various forms, including relapsing-remitting MS (RRMS) or primary progressive MS (PPMS). Technology Description:
Ocrelizumab (Ocrevus) is a humanized monoclonal antibody therapy that is directed toward cluster of differentiation (CD)20, which is a B-cell surface molecule. Ocrelizumab exerts its immunomodulatory effect by selectively depleting CD20-expressing B cells, which may provide therapeutic benefit in immune disorders such as RRMS and PPMS.
Clinical Alternatives:
There are several alternative disease-modifying therapies for MS, including beta
interferons, glatiramer acetate, fingolimod, and natalizumab.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=72926
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antibodies, Monoclonal, Humanized
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.